VLDL receptor

Also Known As:

VLDLR protein, human; Vldlr protein, mouse; Vldlr protein, rat; beta-VLDL receptor; receptor, VLDL; very low density lipoprotein receptor, human; very low density lipoprotein receptor, mouse; very low density lipoprotein receptor, rat; very low density lipoprotein receptors

Networked: 66 relevant articles (5 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Lipoprotein Receptors: 240
        LDL Receptors: 3829
        VLDL receptor: 66

Experts

1.	Takahashi, Sadao: 6 articles (01/2021 - 06/2003)
2.	Vaziri, Nosratola D: 5 articles (11/2009 - 01/2002)
3.	Hattori, Hiroaki: 3 articles (04/2011 - 01/2004)
4.	Miyamori, Isamu: 3 articles (04/2011 - 06/2003)
5.	Yamamoto, Tokuo T: 3 articles (04/2011 - 06/2003)
6.	Liang, Kaihui: 3 articles (07/2004 - 01/2002)
7.	Medved, Leonid: 2 articles (01/2022 - 01/2018)
8.	Yakovlev, Sergiy: 2 articles (01/2022 - 01/2018)
9.	Gao, Lili: 2 articles (11/2014 - 01/2014)
10.	Liang, Yongjun: 2 articles (11/2014 - 01/2014)

Related Diseases

1.	Hypertriglyceridemia 03/22/2002 - "Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency." 01/01/1985 - "Fifth, our observations suggest that the abnormal catabolism of VLDL that occurs in hypertriglyceridemia may be explained by the abnormal uptake of HTG-VLDL by either the LDL or the beta-VLDL receptor pathway. " 03/01/1998 - "Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure." 04/01/2019 - "Chronic fructose intake does not induce liver steatosis and inflammation in female Sprague-Dawley rats, but causes hypertriglyceridemia related to decreased VLDL receptor expression." 07/01/2004 - "Hypertriglyceridemia in nephrotic syndrome is accompanied by increased hepatic fatty acid synthesis, elevated triglyceride secretion, as well as lipoprotein lipase, VLDL-receptor, and hepatic triglyceride lipase deficiencies, which lead to impaired clearance of triglyceride-rich lipoproteins. "
2.	Atherosclerosis 01/01/2021 - "Role of VLDL receptor in atherogenesis." 01/01/2000 - "Although the VLDL receptor has been shown to play an important role in the proliferation of vascular smooth muscle cells and the formation of foam cells as primary responses of atherogenesis, its actual functions are still unclear. " 12/01/1996 - "Our findings suggest that the VLDL receptor expression may play a role in the development of atherosclerosis." 04/22/2011 - "Since VLDL receptor is expressed on macrophages in atheromatous plaques of both rabbit and human but not in mouse models, the mechanisms of atherogenesis and/or growth of atherosclerotic lesions in mouse models may be partly different from those of humans and rabbits." 01/01/1996 - "The VLDL receptor is an essential receptor in avian species and the receptor-deficient mutant hens are sterile and exhibit severe hyperlipidemia with aortic atherosclerosis."
3.	Proteinuria 11/01/2003 - "This study tested the hypothesis that amelioration of proteinuria by protein restriction or use of oral adsorbent AST-120 beginning at 10 weeks of age may improve renal disease and LPL and VLDL receptor deficiencies in Imai rats. " 11/01/2003 - "Protein restriction mitigated the decline in creatinine clearance, ameliorated proteinuria, hypoalbuminemia, hypertension, and hypercholesterolemia, lowered plasma VLDL, and improved plasma postheparin LPL activity, hepatic lipase activity, LPL, and VLDL receptor proteins in skeletal muscle and adipose tissue. "
4.	Hypertension (High Blood Pressure) 12/01/1995 - "2. We studied the gene expression of the VLDL receptor in the heart of stroke-prone spontaneously hypertensive rats (SHRSP), an animal model for hypertension-induced cardiac hypertrophy. " 01/01/1996 - "To elucidate the regulation of very-low density-lipoprotein (VLDL) receptor, we have studied its gene expression in the heart of spontaneously hypertensive rats-stroke prone (SHR-SP, an animal model for hypertension-induced cardiac hypertrophy) compared with Wistar-Kyoto rats. " 01/01/1996 - "RNase protection assay showed that ventricular VLDL receptor mRNA falls to 41% of normal levels at 4 weeks when hypertension is not yet fully developed, and drops further to 14% at 13 weeks, when cardiac hypertrophy is established. " 12/01/1995 - "RNase protection assay showed that the level of ventricular VLDL receptor mRNA was already decreased to one half when hypertension was not fully developed, and further diminished to one fifth when cardiac hypertrophy was established. " 11/01/2003 - "Protein restriction mitigated the decline in creatinine clearance, ameliorated proteinuria, hypoalbuminemia, hypertension, and hypercholesterolemia, lowered plasma VLDL, and improved plasma postheparin LPL activity, hepatic lipase activity, LPL, and VLDL receptor proteins in skeletal muscle and adipose tissue. "
5.	Hypercholesterolemia 01/01/1998 - "Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor." 11/01/2003 - "Protein restriction mitigated the decline in creatinine clearance, ameliorated proteinuria, hypoalbuminemia, hypertension, and hypercholesterolemia, lowered plasma VLDL, and improved plasma postheparin LPL activity, hepatic lipase activity, LPL, and VLDL receptor proteins in skeletal muscle and adipose tissue. "

Related Drugs and Biologics

1.	Lipoproteins (Lipoprotein)
2.	Lipase (Acid Lipase)
3.	Lipoprotein Lipase (Diacylglycerol Lipase)
4.	Triglycerides (Triacylglycerol)
5.	VLDL Lipoproteins
6.	Proteins (Proteins, Gene)
7.	oxidized low density lipoprotein
8.	Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)
9.	Fatty Acids (Saturated Fatty Acids)
10.	Pre-beta High-Density Lipoproteins

Related Therapies and Procedures

1.	Aftercare (After-Treatment)